Advair Diskus Authorized Generic Announced
February 8, 2019 – GlaxoSmithKline has announced plans to launch an authorized generic for its popular Advair Diskus® (fluticasone propionate/salmeterol inhalation powder) product. The announcement comes a week after competitor Mylan announced U.S. FDA approval for Wixela Inhub™, its own generic version of Advair Diskus.
Advair Diskus, which first received FDA approval in 2000, is indicated to treat asthma in individuals who are at least four years of age, as well as to provide maintenance treatment for chronic obstructive pulmonary disorder (COPD). It is one the most commonly prescribed treatments for these conditions, which affect 26 million and 16 million patients in the U.S., respectively.
Although GlaxoSmithKline’s authorized generic will be sold at a discount compared to the list price for the brand name, Mylan’s Wixela Inhub will cost 67% less based on wholesale acquisition cost (WAC).